10:04 AM EDT, 03/28/2025 (MT Newswires) -- Liquidia ( LQDA ) said Friday the US Food and Drug Administration accepted its resubmitted new drug application for Yutrepia inhalation powder to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

The company said the FDA classified the resubmission as a complete, Class 1 response to an August 2024 action letter that granted tentative approval of Yutrepia, or treprostinil.

The agency set a May 24 target action date, Liquidia ( LQDA ) said.

Shares of the company were up 1.5% in recent trading Friday.

Price: 15.47, Change: +0.23, Percent Change: +1.48